Status and challenges of Spiral2 SRF linac

MOIOA02

SPIRAL2 cryomodule production result and analyses

THIOB02International audienceThe production and qualification of the SPIRAL2 cryomodules are close to the end. Their performances arenow well established. This paper will explain the path followed to the good achievements, and show somestatistical analyses to be used for future projects. How far can we push the performances? What cryogenicsconsumption shall we take as design values

Study of a spoke cavity for low-beta applications

Abstract Since a few years, intensive studies have been developed on SC cavities (for instance, spoke-type or reentrant cavities) for their use as accelerating structures in the low energy part of high power proton or ions accelerators (typically from 5 to 100 MeV). Within the framework of the EURISOL (EURopean Isotope Separation On-Line) & XADS (eXperimental Accelerator Driven System) European accelerators projects, IPN Orsay decided to plan a R&D program on low-beta spoke-type cavities. In the major part of this paper, we report on the optimization of the geometry of a β=0.35, 2 gap spoke cavity, aiming at achieving good electromagnetic parameters (i.e. lowest E pk /E acc and B pk /E acc ). A mechanical study is also presented, as well as a preliminary design of a proton spoke Linac (12-85 MeV) composed of β=0.18 and β=0.35, 2 gap cavities

Power couplers for Spiral 2

http://accelconf.web.cern.ch/AccelConf/SRF2011/papers/frioa04.pdf Due to its success, we intend to have a PRST-AB SRF2011 special edition.International audienc

High intensity linac driver for the SPIRAL-2 project : Design of superconducting 88 MHz quarter wave resonators (beta 0.12), power couplers and cryomodules

ACCInternational audienceA Superconducting Linac Driver, delivering deuterons with energy up to 40 MeV (5 mA) and heavy ions with energy of 14.5 MeV/u (1 mA ), is proposed for the Spiral-2 radioactive beams facility. For the high energy section of the linac, a superconducting 88 MHz Quarter Wave Resonator (beta 0.12) has been designed and the optimisation of RF and mechanical performances will be presented. Based on the present state-of-art of the Superconducting RF technology, maximum electric surface field of 40 MV/m and magnetic surface field of 80 mT, have been adopted which should allow to reach an accelerating field of 7 MV/m (energy gain 3 MeV per resonator). A first complete prototype is under construction. The high intensity deuteron beam specifications have imposed the design of an original power coupler (maximum power 20 KW). The RF, mechanical, and thermal characteristics will be presented. The design of the cryomodule for this high energy section, integrating two QWR with its associated equipments (couplers, tuners, helium tanks), will be presented

Spiral2 cryomodules B tests results

MOP010International audienceAssembly and tests of the SPIRAL2 superconducting linac's cryomodules at CEA/Saclay and IPN/Orsay have now reached cruising speed after having faced a series of problems, among them contamination. 19 cryomodules are composing the whole Linac and IPN Orsay is in charge of the 7 cryomodules B, housing two 88 MHz, beta 0.12 Quarter-Wave Resonators. Threecryomodules have been assembled and successfullytested up to the nominal gradient of 6.5 MV/m for all cavities with also cryogenic losses withinspecifications. Two of them are fully qualified and already delivered to GANIL. The thirdone showed misalignment ofone cavity which could lead to partial disassembly if needed. This paper presents the results of those cryomodules tests as well as the status of the remaining ones

Development and evaluation of an intervention based on the provision of patient feedback to improve patient safety in Spanish primary healthcare centres: study protocol

This is the final version. Available on open access from BMJ Publishing Group via the DOI in this recordINTRODUCTION: Despite the enormous potential for adverse events in primary healthcare (PHC), the knowledge about how to improve patient safety in this context is still sparse. We describe the methods for the development and evaluation of an intervention targeted at PHC professionals to improve patient safety in Spanish PHC centres. METHODS AND ANALYSIS: The intervention will consist in using the patient reported experiences and outcomes of safety in primary care (PREOS-PC) survey to gather patient-reported experiences and outcomes concerning the safety of the healthcare patients receive in their PHC centres, and feed that information back to the PHC professionals to help them identify opportunities for safer healthcare provision. The study will involve three stages. Stage 1 (developing the intervention) will involve: (i) qualitative study with 40 PHC providers to optimise the acceptability and perceived utility of the proposed intervention; (ii) Spanish translation, cross-cultural adaptation and validation of the PREOS-PC survey; (iii) developing the intervention components; and (iv) developing an online tool to electronically administrate PREOS-PC and automatically generate feedback reports to PHC centres. Stage 2 (piloting the intervention) will involve a 3-month feasibility (one group pre-post) study in 10 PHC centres (500 patients, 260 providers). Stage 3 (evaluating the intervention) will involve: (i) a 12-month, two-arm, two-level cluster randomised controlled trial (1248 PHC professionals within 48 PHC centres; with randomisation at the centre level in a 1:1 ratio) to evaluate the impact of the intervention on patient safety culture (primary outcome), patient-reported safety experiences and outcomes (using the PREOS-PC survey), and avoidable hospitalisations; (ii) qualitative study with 20 PHC providers to evaluate the acceptability and perceived utility of the intervention and identify implementation barriers. ETHICS AND DISSEMINATION: The study was approved by the Ethics Committee of the Balearic Islands (CEI IB: 3686/18) with the 1964 Helsinki Declaration and its later amendments. The results will be disseminated in peer-reviewed publications and national and international conferences. TRIAL REGISTRATION NUMBER: NCT03837912; pre-results.Instituto de Salud Carlos III (Spanish Ministry of Sciences, Innovation and Universities